Stay updated on Daratumumab Therapy for Refractory AL Amyloidosis Clinical Trial
Sign up to get notified when there's something new on the Daratumumab Therapy for Refractory AL Amyloidosis Clinical Trial page.

Latest updates to the Daratumumab Therapy for Refractory AL Amyloidosis Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an opportunity for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference2%
- Check9 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.3%
- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check38 days agoChange DetectedThe page has been updated to reflect a new version (v2.15.0) and the removal of detailed information about a Phase II study of Daratumumab in AL Amyloidosis patients, including treatment protocols and eligibility criteria.SummaryDifference48%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check96 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
Stay in the know with updates to Daratumumab Therapy for Refractory AL Amyloidosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab Therapy for Refractory AL Amyloidosis Clinical Trial page.